Clinical Trial

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

Study acronym: FACE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-04-04; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2024-06-21
Trial Details
NCT Number NCT06358677
Lead Sponsor University of Utah
Conditions Metastatic Solid Tumor, Locally Advanced Solid Tumor
Enrollment 25 participants
Start Date 2025-02-19
Primary Completion 2027-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-13